TARGETING THE UNIQUE BIOLOGY OF DUCTAL PROSTATE CANCERS USING POLY ADP RIBOSE POLYMERASE PARP INHIBITOR AND ANDROGEN SIGNALING INHIBITOR COMBINATION THERAPY

Monash University, Victoria

Investigators